Latest Information Update: 28 Aug 2002
At a glance
- Originator Novo Nordisk
- Class Osteoporosis therapies; Pyrrolidines
- Mechanism of Action Selective estrogen receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Postmenopausal osteoporosis
Most Recent Events
- 17 Feb 1999 New profile
- 17 Feb 1999 Preclinical development for Postmenopausal osteoporosis in Denmark (PO)